Reneo Pharma up as genetic disorder therapy trial achieves target enrollment

Onkure Therapeutics

14/03/2023 17:22

** Shares of drug developer Reneo Pharmaceuticals Inc
 RPHM.O  rise ~6% to $4.58  
    ** Co says it has achieved target enrollment in a mid-stage
study for its experimental therapy, mavodelpar, to treat a type
of genetic disorder known as primary mitochondrial myopathies
(PMM)  
    ** Highlight that investors have been "eagerly awaiting this
significant milestone" as it could potentially trigger further
run-up of the stock into study's topline data - Piper Sandler
says about the enrollment  
    ** RPHM expects to report the topline data from study in Q4
of 2023
    ** PMM are a group of rare, genetic metabolic disorders that
 hamper the ability of affected cells to break down food and
oxygen and produce energy 
    ** RPHM shares have more than doubled in the past three
months

 (Reporting by Raghav Mahobe)
 ((Raghav.Mahobe@thomsonreuters.com;))